



ASX ANNOUNCEMENT

27 FEBRUARY 2026

## PORTFOLIO STREAMLINED WITH RETURN OF CHM CLTX TO CITY OF HOPE

- Reinforces Chimeric's focus on its CHM CDH17 program

**Sydney, Australia, 27 February 2026:** Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to announce it has entered into an arrangement to return to City of Hope the Chlorotoxin (CHM CLTX) CAR T-cell therapy asset that it had exclusively licensed.

City of Hope will assume full ownership and control of the CHM CLTX intellectual property and associated program. Since in-licensing the CHM CLTX program, Chimeric has advanced and expanded its broader pipeline. The Company's other clinical stage assets have now overtaken CHM CLTX in terms of development priority, resource allocation, and near-term value inflection points.

Following a strategic review of its portfolio, the Board and management determined that discontinuing its development of CHM CLTX asset represents a disciplined capital management decision that aligns with the Company's focus on advancing its core programs.

Chimeric remains focused on progressing its core pipeline, where the Company believes it has the greatest opportunity to generate clinical differentiation and shareholder value.

Chimeric's CEO Dr Rebecca McQualter said: "This decision allows CHM to prioritise programs with the strongest potential for clinical impact and commercial scalability. By streamlining the portfolio, we can deploy capital more efficiently and advance our lead CHM CDH17 program through key development milestones."

"Following a comprehensive portfolio review, the Board determined that returning CHM CLTX to City of Hope represents a disciplined capital allocation decision aligned with our strategic priorities and our commitment to creating long-term value for shareholders. We appreciate City of Hope's collaboration in reaching a constructive outcome for both parties." said Dr Bradley Glover, Chimeric's Non-Executive Chairman.

### ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.



Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.

#### **Contact**

##### Investors

Dr Rebecca McQualter  
Chief Executive Officer  
Chimeric Therapeutics  
E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

##### Media

Matthew Wright  
NWR Communications  
T: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)